Search PeptideClear
Peptides, vetted UK sellers, or GLP-1 clinics. Pick a tab below.
Try a quick search
We have not vetted that site yet.
PeptideClear can audit this source for you for free. Editorial verdict within 72 hours.
Got it. Editorial verdict within 72 hours.
We will email you a link to the published /retailer/[slug]/ profile once the audit lands.
While you wait, 3 already-vetted alternatives
Alternatives are matched to your stated goal. Click-throughs use affiliate links. No price difference for you. How we are funded.
GLP-1 · UK encyclopedia hub 2026
Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)
Last updated 2026-06-12
GLP-1 is a hormone the gut releases after a meal. The medications people search for under "GLP-1" or "weight loss injections" are receptor agonists that bind the same receptor and trigger the same downstream signalling. In the UK there are four licensed brands across three molecules (Mounjaro, Wegovy, Ozempic, Saxenda) and one frequently-searched investigational entry (retatrutide) that is not UK-licensed. They are dispensed through four UK routes: NHS specialist cohorts, private clinic, UK-licensed online pharmacy, and in-store pharmacy. This hub names the medications and routes encyclopedically. It does not rank them, dose them, price them, or recommend one for a specific person. We compare on price and evidence. We do not sell, prescribe, or take payment for placement.
Compare the UK GLP-1 routesEditorial with affiliate links. We earn from purchases via outbound retailer / clinic links. How we are funded.
GLP-1 stands for glucagon-like peptide 1, a gut hormone. The medications searched for as GLP-1 or weight loss injections are GLP-1 receptor agonists. UK-licensed brands in 2026 are Mounjaro (tirzepatide), Wegovy and Ozempic (semaglutide, with separate weight-management and diabetes licences), and Saxenda (liraglutide). Retatrutide is investigational and not UK-licensed. They reach UK patients through four routes: NHS specialist-led services on a phased cohort rollout, private UK clinic, UK-licensed online pharmacy, and in-store pharmacy. This hub names what is in the category and points to the brand pages. It does not dose, price or recommend. Prescription only medicine. Your prescriber decides suitability.
GLP-1 is short for glucagon-like peptide 1. It is a hormone the gut releases after eating. In the body, GLP-1 binds to the GLP-1 receptor on cells in the pancreas, brain, gut and elsewhere. The downstream signalling slows gastric emptying, increases satiety, and influences how the pancreas releases insulin in response to a meal. Those biological effects were described in the academic literature long before the medications existed.
The medications people search for as "GLP-1" or as "weight loss injections" are GLP-1 receptor agonists. They are synthetic peptides that bind the same receptor and trigger the same downstream signalling. Some are pure GLP-1 receptor agonists. Some are dual agonists that also bind the GIP receptor. One investigational entry binds three receptors including the glucagon receptor. The shorthand "GLP-1" in consumer search is broader than the strict pharmacological sense, which is why this hub names the molecules in plain language.
The shorthand "weight loss injection" is even broader and is the term ASA uses in its weight-loss advertising rules. In practice, in the UK in 2026, every weight-loss injection on the licensed market is a GLP-1 or GLP-1-containing receptor agonist. The two phrases point at the same category from different angles. Other approaches to weight loss exist outside this hub.
Factual list of the brands UK searchers encounter, with the international non-proprietary name (INN), the UK licence position, and a short editorial note. Not a ranking. Not a recommendation. The full per-brand encyclopedia and the per-route pricing live behind the linked pages.
UK licensing
UK-licensed for type 2 diabetes and for weight management in adults with obesity or overweight with at least one weight-related comorbidity, under specialist or appropriately qualified prescriber supervision.
Dual GIP and GLP-1 receptor agonist. Manufactured by Eli Lilly. The most-searched UK weight-loss medication in 2026.
Read more →UK licensing
UK-licensed for chronic weight management in adults with obesity or overweight with weight-related comorbidities, under specialist criteria reflected in NICE TA875.
GLP-1 receptor agonist. Manufactured by Novo Nordisk. The weight-management licence of semaglutide; Ozempic is the type 2 diabetes licence of the same molecule.
Read more →UK licensing
UK-licensed for type 2 diabetes. Not licensed for weight management in the UK; the weight-management licence of semaglutide is Wegovy.
Same active molecule as Wegovy under a different brand and licence. Off-label use for weight loss is a prescriber decision and not the route this hub covers.
Read more →UK licensing
UK-licensed for weight management as an adjunct to a reduced-calorie diet and increased physical activity in adults with obesity or overweight with weight-related comorbidities.
Older daily-injection GLP-1 receptor agonist. The first GLP-1 medication to receive a UK weight-management licence. Less commonly prescribed in 2026 as weekly options expanded.
Read more →UK licensing
Investigational. Not licensed in the UK as of 2026. In phase 3 trials by Eli Lilly. Frequently searched but not a dispensable UK product.
Triple agonist at GLP-1, GIP and glucagon receptors. Included here for completeness because UK search demand exists. Not available through any UK route on this site.
Read more →In the UK in 2026, GLP-1 medication reaches patients through four broad routes. Each is regulated differently and serves a different starting point. Choosing between them is a route question, not a brand question. The brand the user ends up on is a prescriber decision.
Free at point of use. Specialist Tier 3 or Tier 4 referral.
NHS England rolled GLP-1 medication for weight management out in phased cohorts through specialist weight-management services. Eligibility is tightly defined and access is via GP referral into a Tier 3 or Tier 4 specialist service, not direct request. Geographic availability varies by Integrated Care Board.
Open the hub →Subscription. Coach, app, prescriber oversight.
High-touch private operators bundle the medication with a structured programme: digital coach, dose progression app, prescriber check-ins and in some cases blood tests. GPhC pharmacy registration and GMC-registered prescribers throughout.
Open the hub →Per-month dispensing. Online questionnaire consult.
UK-licensed online pharmacies dispense the same medication against an online questionnaire and prescriber review. No structured coaching layer. The maintenance route once a patient is stable on dose, or a price-led route for an existing user.
Open the hub →Walk-in. NHS Electronic Prescription Service endpoint.
High-street pharmacies are the NHS Electronic Prescription Service endpoint for NHS-issued weight-management prescriptions. Some chains and supermarket pharmacies also offer a private weight-management consultation in person, depending on whether the branch has a prescribing pharmacist.
Open the hub →A common UK search is "weight loss injections NHS" or "NHS weight loss injections UK". The short answer is that NHS England rolled GLP-1 medication for weight management out through specialist weight-management services on a phased cohort basis, not as a direct GP prescription that anybody can request at their practice. Eligibility is set centrally and access is via referral into a Tier 3 or Tier 4 specialist service.
The NICE technology appraisal that underpins the weight-management licence and the NHS access page on this site cover the current cohort definitions, the Integrated Care Board variation, and the practical question of how long the referral pathway takes in 2026. We update that page as the cohort criteria expand.
For users who do not meet the NHS cohort criteria but are searching for "NHS weight loss injections" because that is the most familiar phrase, the editorial honest answer is that the UK-licensed private routes are the only legitimate way to access these medications outside the NHS cohorts. Routes outside the UK regulatory frame, including grey-market import or compounded versions, are not covered on this site for safety and legal reasons.
This hub is encyclopedic. It is deliberately silent on a set of clinical questions that belong with a prescriber and with the medication's Summary of Product Characteristics (SmPC) and Patient Information Leaflet (PIL), not with an editorial site. The list below is not exhaustive and is not a hierarchy.
For each of those, the right reference is the SmPC for the specific medication on the MHRA Products portal, the PIL inside the pack, and a GMC-registered prescriber who can take a personal history and decide.
From this umbrella, the natural next steps are the per-brand pages, the route comparison, the NHS access editorial, and the brand-confusion explainers that unpack why semaglutide is searched as three different brand names.
NHS specialist, private clinic, online pharmacy, walk-in. Route-by-route framing for the user choosing where to start.
High-touch private clinics with coach, app and prescriber. Numan, Voy, Manual, Juniper.
Phlo, Pharmacy2U, SimplyMeds, Boots Online Doctor, Asda Online Doctor. Per-month dispensing.
Boots Online Doctor, Modern Chemistry, Boots Bioscience and the supplement shelf.
Current NHS specialist-led cohorts for weight-management medication. Eligibility and pathway.
Common questions on UK access, contraception, pregnancy, side effects and switching.
Why the two are searched as if interchangeable and how the UK licences actually sit.
The molecule-to-brand map across Mounjaro, Wegovy and Ozempic.
Weekly semaglutide vs daily liraglutide, and what the older Saxenda licence covers.
Also on PeptideClear
Research peptides
Encyclopedia and UK retailers
If you also care about the research-tier peptide literature, the encyclopedia covers BPC-157, MOTS-c, GHK-Cu, Ipamorelin and others under research-use-only framing.
VisitCollagen
Marine, bovine, vegan compared
If you also care about ingestible collagen, the hub compares UK brands on type, sourcing, kDa and dose per serving.
VisitCosmetic peptides
UK skincare with GHK-Cu, Matrixyl
If you also care about topical peptide skincare, the cosmetic peptides hub compares UK serums and creams on declared INCI position.
VisitReady to buy
GMC-registered prescribers compared by price, consultation type, and refund policy. Editorial only. We do not prescribe.
PeptideClear is a trading name of Best Business Loans Ltd, registered in England and Wales (company number 16833937). All services, operations and publications under the PeptideClear brand are delivered by Best Business Loans Ltd.
Registered in England and Wales. Company number 16833937. D‑U‑N‑S 234324824. ICO registered, reference ZC151816 (certificate, verify). Registered supplier on the UK Government's Find a Tender Service (FTS). Details publicly available via Companies House and OpenCorporates.
Operates under UK data protection and consumer standards. Aligns with UK GDPR, ISO 27001 and ISO 9001 principles. Working towards Cyber Essentials certification.
Primary domain peptideclear.co.uk. Business ownership, entity and services remain unchanged. Reviewed quarterly.
We earn from purchases made via outbound links to retailers, clinics, and pharmacies. Specific commercial relationships per page are declared inline. How we are funded.